CN106170491B - 神经保护肽 - Google Patents

神经保护肽 Download PDF

Info

Publication number
CN106170491B
CN106170491B CN201480071971.3A CN201480071971A CN106170491B CN 106170491 B CN106170491 B CN 106170491B CN 201480071971 A CN201480071971 A CN 201480071971A CN 106170491 B CN106170491 B CN 106170491B
Authority
CN
China
Prior art keywords
peptide
peptides
glutamate
protamine
neuroprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480071971.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN106170491A (zh
Inventor
B·梅洛尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algenica Therapeutics Ltd
Original Assignee
Algenica Therapeutics Ltd
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904197A external-priority patent/AU2013904197A0/en
Application filed by Algenica Therapeutics Ltd, University of Western Australia filed Critical Algenica Therapeutics Ltd
Publication of CN106170491A publication Critical patent/CN106170491A/zh
Application granted granted Critical
Publication of CN106170491B publication Critical patent/CN106170491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
CN201480071971.3A 2013-10-30 2014-10-30 神经保护肽 Active CN106170491B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2013904197A AU2013904197A0 (en) 2013-10-30 Neuroprotective peptides
AU2013904197 2013-10-30
AU2014902319A AU2014902319A0 (en) 2014-06-17 Neuroprotective peptides
AU2014902319 2014-06-17
PCT/AU2014/050326 WO2015061856A1 (en) 2013-10-30 2014-10-30 Neuroprotective peptides

Publications (2)

Publication Number Publication Date
CN106170491A CN106170491A (zh) 2016-11-30
CN106170491B true CN106170491B (zh) 2020-07-24

Family

ID=53003020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480071971.3A Active CN106170491B (zh) 2013-10-30 2014-10-30 神经保护肽

Country Status (7)

Country Link
US (3) US20160250285A1 (enExample)
EP (1) EP3063168B1 (enExample)
JP (1) JP6495270B2 (enExample)
CN (1) CN106170491B (enExample)
DK (1) DK3063168T3 (enExample)
ES (1) ES2724932T3 (enExample)
WO (1) WO2015061856A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303063B2 (en) * 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
WO2014202834A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Protamine in treatment of neuronal injuries
CN106170491B (zh) 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽
ES2896224T3 (es) * 2016-06-23 2022-02-24 Japan Science & Tech Agency Composición farmacéutica que comprende arginina para su uso en el tratamiento de la enfermedad de PolyQ
US10774122B2 (en) * 2017-03-21 2020-09-15 The Regents Of The University Of Michigan ERG targeted therapy
AU2018247561A1 (en) * 2017-04-02 2020-11-26 Interk Peptide Therapeutics Limited Compositions and methods for prophylaxis or treatment of pain
JP2022505101A (ja) * 2018-10-18 2022-01-14 ファンダメンタル ファーマ ゲーエムベーハー Ｎｍｄａ受容体媒介毒性を調節するための新規の方法
JP2021116244A (ja) * 2020-01-23 2021-08-10 有機合成薬品工業株式会社 高純度プロタミン硫酸塩
CN115385987B (zh) * 2021-05-19 2024-08-02 中山大学 一种抗鱼类神经坏死病毒的穿膜肽及其应用
JP2023022363A (ja) * 2021-08-03 2023-02-15 国立大学法人北海道大学 細胞保護用剤
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
WO2026099761A1 (en) 2024-11-06 2026-05-15 Salem Yahya Ahmed Peptides
CN119563880B (zh) * 2025-01-24 2025-07-15 浙江工业大学 一种多肽负载沙棘果油微囊粉及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1692126A (zh) * 2002-10-07 2005-11-02 路德维希癌症研究院 P53结合多肽
WO2011063320A2 (en) * 2009-11-23 2011-05-26 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
WO2013158739A1 (en) * 2012-04-17 2013-10-24 Brown University Neuroprotective composition and method of use

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4684624A (en) 1983-12-22 1987-08-04 Yoshio Hosobuchi Method of treating cerebral ischemia
US5559095A (en) 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
WO1998041223A1 (en) 1997-03-20 1998-09-24 The Regents Of The University Of California N-methyl-d-aspartate receptor channel blockers and method for identifying such
US6605115B1 (en) * 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
DE60230071D1 (de) 2002-06-14 2009-01-08 Monier Tadros Methode für die herstellung von protamin
JP2007526316A (ja) 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
GB0702022D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
WO2008133929A2 (en) * 2007-04-24 2008-11-06 Yale University Cell permeable miniature proteins
KR20090034239A (ko) * 2007-10-02 2009-04-07 재단법인서울대학교산학협력재단 골형성 촉진용 세포투과성 융합 단백질 및 그 용도
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
CA2990678C (en) 2009-11-06 2021-08-31 The J. David Gladstone Institutes Methods and compositions for modulating tau levels
US20120301446A1 (en) 2010-02-04 2012-11-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2013076666A1 (en) * 2011-11-23 2013-05-30 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
CA2857287A1 (en) 2011-11-29 2013-06-06 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of active agents across the blood-brain barrier
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
EP2986115A4 (en) 2013-02-06 2017-03-01 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
WO2014202834A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Protamine in treatment of neuronal injuries
CN106170491B (zh) 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1692126A (zh) * 2002-10-07 2005-11-02 路德维希癌症研究院 P53结合多肽
WO2011063320A2 (en) * 2009-11-23 2011-05-26 Research Development Foundation Recombinant filaggrin polypeptides for cell importation
WO2013158739A1 (en) * 2012-04-17 2013-10-24 Brown University Neuroprotective composition and method of use

Also Published As

Publication number Publication date
EP3063168B1 (en) 2019-03-06
US20180326001A1 (en) 2018-11-15
EP3063168A4 (en) 2017-03-22
DK3063168T3 (en) 2019-04-15
JP6495270B2 (ja) 2019-04-03
JP2016540739A (ja) 2016-12-28
EP3063168A1 (en) 2016-09-07
CN106170491A (zh) 2016-11-30
US12303550B2 (en) 2025-05-20
US20160250285A1 (en) 2016-09-01
US20220111003A1 (en) 2022-04-14
US11229678B2 (en) 2022-01-25
WO2015061856A1 (en) 2015-05-07
ES2724932T3 (es) 2019-09-17

Similar Documents

Publication Publication Date Title
US12303550B2 (en) Neuroprotective peptides
KR101999756B1 (ko) Ｃｄ36 발현을 감소시키는 방법
US7718610B2 (en) Retrocyclins: antiviral and antimicrobial peptides
CN102666845B (zh) 磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法
US6713078B2 (en) Retrocyclins: antiviral and antimicrobial peptides
EP1389126B1 (en) Retrocyclins: antiviral and antimicrobial peptides
MacDougall et al. In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection
CA3022763A1 (en) Novel peptides and peptidomimetics
US20170114093A1 (en) Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection
WO2013163567A2 (en) Novel alpha-helical peptidomimetic inhibitors and methods using same
HK1242610A1 (en) Methods for reducing cd36 expression
HK1197994A (en) Methods for reducing cd36 expression
HK1197994B (en) Methods for reducing cd36 expression
HK1123992B (en) Methods for reducing cd36 expression
HK1173367B (en) Methods for reducing cd36 expression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200623

Address after: Western Australia

Applicant after: Algenica therapeutics Limited

Address before: Western Australia

Applicant before: The University of Western Australia

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant